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INTRODUCTION
Trichosporon beigelii is found in soil and occasionally as a part
of the normal flora in human skin (1). The fungus is a causa-
tive agent of white piedra, an innocuous superficial hair shaft
infection in immunocompetent individuals, and rarely of
disseminated trichosporonosis in immunocompromised pa-
tients (1). Recently, with more aggressive chemotherapy for
malignant diseases and increasing use of broad-spectrum
antibiotics, a large number of cases of disseminated tricho-
sporonosis have been reported (1, 2). 
Here, we describe the first case of disseminated T. beigelii
infection in a Korean patient, during a neutropenic period
by chemotherapy for myelodysplastic syndrome. The other
reported case in Korea was a patient with advanced gastric
cancer and normal neutrophil count and without systemic
symptoms (2). 
CASE REPORT
A 41-yr-old male patient, with myelodysplastic syndrome
of refractory anemia with an excess of blasts in transforma-
tion received an induction chemotherapy with cytosine ara-
binoside and idarubicin. On the fifth day of the chemother-
apy, his absolute neutrophil count (ANC) declined to 142/ L,
which prompted the treatment with granulocyte colony sti-
mulating factor (G-CSF). On the 14th day, his bone marrow
showed complete clearance of the neoplastic cells and hypo-
celluar marrow. The patient’ s cytopenia was supported with
multiple transfusions of red blood cells, platelets, and plasma.
On the 15th day, administration of empirical broad-spectrum
antibiotics was promptly started because of the development
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A Case of Disseminated Trichosporon beigelii Infection in a Patient
with Myelodysplastic Syndrome after Chemotherapy
Trichosporonosis is a potentially life-threatening infection with Trichosporon
beigelii, the causative agent of white piedra. The systemic infection by this fungus
has been most frequently described in immunocompromised hosts with neu-
tropenia. Here, we report the first patient with disseminated infection by T. beigelii
in Korea, acquired during a period of severe neutropenia after chemo-therapy for
myelodysplastic syndrome. The patient recovered from the infection after an
early-intensified treatment with amphotericin B and a rapid neutrophil recovery.
The disseminated infection by T. beigelii is still rare, however, is an emerging
fatal mycosis in immunocompromised patients with severe neutropenia.
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Fig. 1. Skin lesion, trunk: multiple erythematous nodules subse-
quently proved to be due to Trichosporon beigelii by biopsy. 
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of fever and dry cough with both lower lungs infiltrates of
reticulonodular pattern. Erythematous maculonodular skin
lesions were noticed on his face and trunk as well (Fig. 1).
Three days later, he was still febrile and chest radiography
showed progression of the infiltration. A prompt empirical
administration of amphotericin B was started. On the 20th
day, fever continued and pneumonic infiltration in both lower
lungs was aggravated despite negative sputum cultures.
Central venous catheter was then removed and antibiotic
agents were changed to imipenem, vancomycin and ampho-
tericin B. On the 25th day of the chemotherapy, the multi-
ple skin nodules had extended to the extremities and skin
biopsy was done on the trunk (Fig. 2). At this point, blood
cultures taken prior to antifungal therapy revealed a growth
of  T. beigelii (Fig. 3), which was identified by Microscan Rapid
Yeast ID panel (Dade Behring, U.S.A.). However, repeated
urine, sputum, and central venous catheter tip cultures were
negative. On the 26th day, ANC was 748/ L, then G-CSF
was discontinued. On the 30th day, the fever subsided with
a good recovery of white cell count and the patient continued
to receive high dose amphotericin B (1 mg/kg) daily. On the
44th day, chest radiograph was normal and skin nodules re-
solved completely. Follow-up blood, urine, and sputum cul-
tures were negative, and cumulative total amphotericin B
dose was 1,430 mg. However, three days later, fever developed
again with skin nodules on the face. A combination therapy
with amphotericin B (1.5 mg/kg/day) and itraconazole was
initiated. Two days later, the patient became afebrile and skin
lesions resolved. Antifungal treatment was continued on an
outpatient basis (amphotericin B, a total dose of 3,144 mg).
Neither further chemotherapy nor bone marrow transplan-
tation was performed for fear of reactivation of the fungal
infection. One month later, the patient died of septic shock,
but T. beigelii was not detected in any of the microbiological
isolates.
DISCUSSION
T. beigelii is classically associated with superficial hair infec-
tions, known as white piedra. More recently, it has been rec-
ognized as an opportunistic pathogen that can cause a po-
tentially fatal systemic infection in immunocompromised
hosts (1, 2). Patients with hematologic malignancies receiv-
ing cytotoxic chemotherapy have been most frequently re-
ported to develop trichosporonosis. However, trichosporono-
sis has also been reported in non-neutropenic patients (1, 2). 
A review of the literature suggests that the origin of T.
beigelii is generally exogenous. Now, the three most common
portals of entry are thought to be the respiratory tract, gas-
trointestine, and skin (wound or catheter-associated) (1, 3,
4). Cytotoxic anti-cancer drug (cytosine arabinoside) may
injure the mucosa of the gastrointestinal tract, and broad-
spectrum antibiotics can severely disrupt the normal micro-
biologic flora of the gastrointestinal tract. Trichosporon may
then colonize, proliferate, and invade the blood vessels through
the disrupted mucosal barrier. Hematogenous dissemination
is usually rapid and widespread (5). However, in T. beigelii
Fig. 2. Skin biopsy, trunk: the central area of dermal necrosis
contains narrow, irreguarly septate pseudohyphae and large
pleomorphic yeast forms of fungi with arthroconidia and blasto-
conidia, which are morphologically consistent with T. beigelii
(H&E, ×200).
Fig. 3. Microscopic morphology of T. beigelii from the colony on
agar plate: true hyphae and pseudohyphae with blastoconidia
are seen singly or in short chains (Gram stain, ×400).Disseminated T. beigelli Infection in MDS 507
pneumonia, the fungi were present predominantly in the
brochoalveolar spaces. It is generally regarded that the lung
involvement is primary rather than secondary from  hema-
togenous spread (5). In this case, the patient presented with
fever, respiratory symptoms and chest radiograph abnormal-
ities, followed by skin manifestations. Surveillance fungal
cultures of stool and sputum were not performed, however,
central venous catheter tip culture was negative. Therefore,
we presumed the respiratory tract was the portal of entry,
although the gastrointestinal tract can not be excluded.
The clinical manifestations of trichosporonosis are variable.
The lung, kidneys, skin, liver, spleen, and heart are the most
frequently affected organs. Cutaneous involvement occurs
in approximately 30% of patients with trichosporonosis (3).
The lesions are most frequently described as purpuric papules
and nodules with central necrosis or ulceration. The trunk,
arms, and face were most commonly involved (6). Biopsy
and culture specimens of cutaneous lesions associated with a
disseminated disease may help establish an early diagnosis.
The most frequent histologic pattern is dermal invasion by
fungal elements. Vasculitis and blood vessel thrombosis have
also been reported (6). Although the microscopic appearance
can be confused with Candida or Aspergillus, a close obser-
vation of biopsy specimens containing T. beigelii reveals pseud-
ohyphae, the presence of numerous rectangular arthroconi-
dia, and a few blastoconidia permitting an accurate diagno-
sis. Fungal culture of cutaneous lesions is positive in greater
than 90% of cases and can minimize the possibility of mis-
taken histologic identification (6). Diagnosis of trichosporo-
nosis relies mostly on characterization of the yeast from blood
cultures. In the present case, although we did not culture the
skin biopsy specimen, blood cultures were positive.
The clinical manifestations of T. beigelii pneumonia are fever
unresponsive to antibacterial agents, dyspnea, cough, bloody
sputum, fungemia, associated skin lesions, chorioretinitis,
hematuria, renal failure, and liver dysfunction due to a dis-
seminated infection (5). In neutropenic patients, the most
frequent pattern of pulmonary infiltrates on chest radiographs
is diffuse alveolar infiltrates. Diffuse interstitial infiltrates
and patchy reticulonodular infiltrates may also appear. In
non-neutropenic patients, however, lobar consolidation or
bronchopneumonia is the major characteristic on chest radio-
graphs, and cavitation can sometimes be observed in the in-
filtration. Because chest radiographs of T. beigelii pneumonia
may show diffuse infiltrates, differential diagnosis from pneu-
monia due to Cytomegalovirus or Pneumocystis carinii is im-
portant (5). 
Established treatment modality for T. beigelii is not avail-
able for several reasons. First, the antifungal susceptibility
test is currently not standardized. Walsh et al. demonstrat-
ed that the growth of some strains of T. beigelii were inhibit-
ed, but they were not killed, at safely achievable serum con-
centrations of amphotericin B (7). In addition, there are
conflicting results regarding the susceptibilities to flucyto-
sine, miconazole, and ketoconazole (1). For example, Gold
et al. demonstrated that the MICs of the latter three drugs
varied according to the testing methods (8). Second, the cor-
relation between the in vitro antifungal susceptibility and
the clinical response is not clearly defined  yet (9). Third, the
minimum lethal concentrations which are more important
than MICs in predicting the antifungal activity against T.
beigelii in neutropenic patients, are many times greater than
the MICs and cannot be tolerated by the patient (3, 7). Fourth,
neutropenia is obviously an important factor in triggering a
disseminated trichosporonosis because polymorphonuclear
cells play a major role in the defense against the fungal in-
fection. It appears that a successful therapy has been achie-
ved in the majority of patients recovering from myelosup-
pression. On the other hand, persistent severe neutropenia is
almost always associated with therapeutic failure (10). Last-
ly, the activity of amphotericin B varies by strains, exhibiting
a good in vivo response in some and relative resistance in
others, which suggests that the T. beigelii species may be a
heterogeneous group of the organisms (11).
Recently, some reports indicated azoles (e.g. fluconazole
and SCH-39304) were effective in clearing the fungi in tis-
sue with a good safety profile, and thus could represent an
alternative to amphotericin B for the treatment of trichos-
poronosis (7, 10, 12, 13). Anaissie et al. suggest that ampho-
tericin B and azoles act synergistically against murine tri-
chosporonosis (10). In neutropenic patients, the success of
treatment was associated with resolution of neutropenia and
pretreatment of human monocytes with granulocyte-macro-
phage colony-stimulating factor (GM-CSF), or interferon- ,
which resulted in an enhanced fungicidal activity (14).
However, the agent most commonly used to treat patients
with trichosporonosis is still amphotericin B. Additional
agents used in combination with amphotericin B, such as
rifampin and azoles, have occasionally been shown to be sy-
nergistic in vitro (11). Hematopoietic growth factor is also
recommended in neutropenic patients (14). In the present
case, the therapy was initiated with administration of G-CSF
and amphotericin B. The patient recovered with increase in
white blood cell counts but relapsed after the discontinuation
of the therapy. Therefore, the combination therapy with am-
photericin B and itraconazole was started which attained re-
mission. 
With the increased employment of intensive cytotoxic
chemotherapy and the use of extended courses of antibiotic
therapy, infections due to opportunistic fungi are increasing.
Recognition of T. beigelii as a potential pathogen, especially
in susceptible clinical settings, will lead to the early identi-
fication of this potentially serious infection and the estab-
lishment of appropriate treatment will improve survival.
Disseminated infection with T. beigelii is still rare, however,
is an emerging fatal mycosis in immunocompromised pa-
tients with profound neutropenia.508 J.-C. Kim, Y.S. Kim, C.-S. Park, et al.
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